Herley Reports Second Quarter Results( Conference Call Scheduled ...),Health
Navigation Links
Herley Reports Second Quarter Results
Date:3/12/2008
Conference Call Scheduled for Thursday, March 13, 2008
LANCASTER, Pa., March 12 /PRNewswire-FirstCall/ -- Herley Industries, Inc. (Nasdaq: HRLY) today reported financial results for the second quarter ended February 3, 2008.
Net sales for the fourteen weeks ended February 3, 2008 were approximately $34.7 million. Net loss for the period was approximately $3.8 million or $(.28) per share.
Myron Levy, the Company's Chairman and CEO, will host a conference call on March 13, 2008 at 9:00 a.m. Eastern time to discuss financial results for the second quarter ended February 3, 2008. To join the conference call dial 1 (888) 425-4188, referencing Conference ID 37410642.
A taped replay of the call will be available on March 13, 2008 at 11:00 a.m. through March 20, 2008 at 11:59 p.m. Eastern time. To listen to the replay dial: 1 (800) 642-1687 (U.S.) or 1 (706) 645-9291 (International), and Conference ID 37410642.
In addition, the conference call will be broadcast live over the Internet and can be accessed through the following URL: http://www.videonewswire.com/event.asp?id=46459 . To listen to the live call on the Internet, go to the web site at least 15 minutes early to register, download and install any necessary audio software.
Herley Industries, Inc. is a leader in the design, development and
manufacture of microwave technology solutions for the defense, aerospace
and medical industries worldwide. Based in Lancaster, PA, Herley has eight
manufacturing locations and approximately 985 employees. Additional
information about the company can be found on the Internet at
http://www.
'/>"/>
| SOURCE Herley Industries, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Herley Reports 4th Quarter and Year-End Results
2. Herley Industries, Inc. Receives a $5 Million Award from EDO for Electronic Components for IEDs
3. Herley Industries Announces the Passing of Its Former President
4. Herley Industries, Inc. Second Quarter Earnings Release and Conference Call Notice
5. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
6. Haemacure Reports Third Quarter 2007 Results
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
11. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
Post Your Comments:
(Date:1/8/2009)... Brain perfusion application is...e using the Ziostation® thin-client system. ,...B) January 8, 2009 -- Ziosoft®, Inc. , a lead... for medical imaging , today announced that it ha... Drug Administration (FDA) for its CT brain perfus...
(Date:1/7/2009)...ATTLE, Jan. 8 Cell Thera...ed today that they received $7.5 million pursuant ...rmaceuticals, Inc. to commercialize and develop Ze...mpany received the initial $7.5 million payment in... The Company may earn up to an additional $15 mill...
(Date:1/7/2009)...TON The drive toward containing health care costs... physician productivity, impairing quality and per...ess Medical Center physicians suggest in a New En...g studies in behavioral economics and psychology, ...ss the fear that assigning a monetary value to eve...
(Date:1/7/2009)...ARCOS, Calif., Jan, 7 Natural Alternatives Intern... formulator, manufacturer and marketer of customiz...ffective December 31, 2008 its former President, R...I also announced it completed certain amendments t...g other changes the amendments extend the maturity...
Breaking Medicine News(10 mins):Health News:Ziosoft Receives FDA Clearance for CT Brain Perfusion Application 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Cost containment focus could have consequences for health care delivery 2Health News:Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension 2[0] Ziosoft Receives FDA Clearance for CT Brain Perfusion Application[0] Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals[0] Cost containment focus could have consequences for health care delivery[0] Natural Alternatives International, Inc. Announces Change in Executive Officer and Loan Modification and Extension
...to the conference held at Varca in Goa it is found...rom high homocysteine levels. //The two day confe...und that extreme vegetarian practices lead to hype...ituation by increasing the risk of developing dise...
...onship between obesity in childhood and extent of ...ording to a recent study based on Scottish childre...derlying connection between the extent of physical...e finding hovered around the importance of genetic...
...Kashmir health department today advised people to ...ood of increase in water-borne diseases like diarr...ve been asked to boil drinking water for at least ...getables and fruit thoroughly before eating, an of...
...udies published in the Mayo Clinic Proceedings rev...awal and cocaine use with the onset of cardiac syn...cterized by chest pain, shortness of breath mimics...hed light on ‘broken heart syndrome,’ a still some...
Other Medicine News:Health News:Sudden Opioid Withdrawal Results in ‘Broken Heart Syndrome 2(Date:1/7/2009)...wswire-USNewswire/ -- Scientists have identified m...of relapse in children with acute lymphoblastic le...t further research is needed to determine how chan...to leukemia relapse, the findings are likely to pr...ess the risk of treatment failure. By using a mole...
(Date:1/7/2009)... 7 Circassia Ltd, a specialty,bio...ical care, today,announced that following success...leroMune(R) anti-allergy technology, the company h...r phase II clinical trial in cat allergy. The,stu... patients with confirmed,cat allergies, and all t...
(Date:1/6/2009)...wswire-USNewswire/ -- Sequella, Inc., a clinical-s... of epidemic potential, announced today that SQ109...erculosis (TB), was the first drug approved for ev...act to Dynport Vaccine Company LLC and Quintiles T...l Institute of Allergy and Infectious Diseases (NI...
(Date:1/5/2009)...RNewswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: ...vel, proprietary,antibodies for the treatment of ...vides an outlook on key events anticipated for the... an update on its research and development,progra...o 16, 2009: Update on several preclinical BiTE ant...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 13139 1Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 13139 2ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 13137 1ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 13137 2ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 13137 3ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 13137 4Large source of nitrate a potential water contaminant found in near surface desert soils 13135 1Large source of nitrate a potential water contaminant found in near surface desert soils 13135 2Large source of nitrate a potential water contaminant found in near surface desert soils 13135 3Springer to publish International Journal of Hematology 13133 1Springer to publish International Journal of Hematology 13133 2...HLIEREN (Zurich), Switzerland, March 13, 2007 -,Cy...itive results,from a phase IIa study with CYT003-Q...he treatment of allergic diseases. The study,inclu...lergic,rhinitis due to grass pollen allergy (hay f...ting the safety, tolerability and,exploratory effi...
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
Other Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |